OTHER FUNCTIONS SILOAM"PHASE I, TOPIC 309, LOW VOLUME, ULTRA-SENSITIVE IMMUNODIA

该SBIR项目的目标是开发一种低损失，超灵敏的免疫诊断系统，用于以少量样品快速测量多种癌症生物标志物。医生可以使用该系统来改善癌症的早期检测、诊断、预后和治疗监测。 癌症生物标志物已广泛用于癌症的早期检测和诊断。使用多种癌症生物标志物的测定可以显著增加灵敏度和特异性。目前的检测平台在有效满足这些需求方面受到多种限制。快速、可在低样品体积下工作的仪器通常是昂贵的并且具有有限的灵敏度。超高灵敏度平台也是昂贵的，并且通常需要复杂的样品制备步骤和大的样品体积。Siloam开发了一种新型的微流控分析平台，用于测量多种分析物，灵敏度为20倍，样品和试剂消耗量减少20倍，总分析时间少于20分钟。该技术的使用允许有限的自动化系统作为全自动免疫诊断分析仪操作。 癌症是全球死亡的主要原因。预计2011年美国将发生571，950例癌症死亡。免疫诊断系统可以帮助早期癌症检测和诊断，并直接有助于降低死亡率/医疗保健负担。

The goal of this SBIR project is to develop a low lost, ultrasensitive immunodiagnostic system for measuring multiple cancer biomarkers rapidly with small amount of samples. This system can be used by physicians to improve cancer early detection, diagnosis, prognosis and treatment monitoring. Cancer biomarkers have been widely used for cancer early detection and diagnosis. Assay with multiple cancer biomarkers can significantly increase the sensitivity and specificity. Current detection platforms are limited in multiple ways to effectively address those needs. Instruments that are fast, can work with low sample volumes are typically expensive and have limited sensitivity. Ultra-high sensitivity platforms are also expensive and typically require complex sample prep steps and large sample volumes. Siloam has developed a novel ¿Optimiser¿ microfluidic assay platform, for meauring multiple analytes with 20x sensitivity, 20x less sample and reagent consumption and total assay times less than 20 minutes. Use of this technology allows for limited automation system to operate as a fully automated immunodiagnostic analyzer. Cancer is the leading cause of deaths worldwide. 571,950 deaths from cancer are projected to occur in US in the 2011. The Immunodiagnostic system can help in early cancer detection and diagnosis and directly contribute to reduced mortality/healthcare burden.